JTPM
Journal of Translational and Practical Medicine

Journal of Translational and Practical Medicine regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

eISSN: 2822-5082
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Timing of adjuvant chemoradiation for pancreatic cancer with positive surgical margins
Abstract
Aims: Impact of adjuvant chemoradiation timing on the outcome of pancreatic cancer patients with positive surgical margins is unknown. The aim of this study was to evaluate the effect of adjuvant chemoradiation timing for margin positive pancreatic cancer patients.
Methods: A total of 36 pancreatic adenocarcinoma patients with positive surgical margins and received adjuvant chemoradiation were included in the study. The median radiation dose was 50.4 Gy in 28 fractions. The primary study variable was the timing of chemoradiation, grouped as immediate (after ? 1 cycle of chemotherapy) and delayed (after two or more cycles of chemotherapy) chemoradiation. Gemcitabine (n = 16) and capecitabine (n = 20) were chemotherapy regimens administered with radiation.
Results: Median follow-up time was 23.7 months. Thirteen patients (36%) received immediate and 23 (64%) received delayed chemoradiation. For immediate and delayed treatment groups, median overall survival was 13.5 and 42.5 months, and disease-free survival was 6.4 and 18.8 months, respectively. Disease-free survival and overall survival were better with delayed chemoradiation (p = 0.02). However, the two groups did not significantly differ in locoregional control (p = 0.96).
Conclusion: Delaying chemoradiation until completion of systemic therapy improves disease-free survival and overall survival without any difference in locoregional failure compared to early chemoradiation in pancreatic cancer patients with positive surgical margins.

Keywords : Pancreatic cancer, positive margin, chemoradiation timing, prognosis

Download Article


1. Winter JM, Cameron JL, Campbell KA, et al. 1423pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 2006;10(9):1199-210;discussion 1210-1.
2. Raut CP, Tseng JF, Sun CC, et al. Impact of resection status onpattern of failure and survival after pancreaticoduodenectomy forpancreatic adenocarcinoma. Ann Surg. 2007;246(1):52-60.
3. Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancerresections are R1 resections. Ann Surg Oncol. 2008;15(6):1651-60.
4. Verbeke CS, Menon KV. Redefining resection margin status inpancreatic cancer. HPB (Oxford). 2009;11(4):282-9.
5. Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ, PistersPW. Combined modality treatment of resectable and borderlineresectable pancreas cancer: expert consensus statement. Ann SurgOncol. 2009;16(7):1751-6.
6. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy withgemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlledtrial. JAMA. 2007;297(3):267-77.
7. Park S, Kim SC, Hong SM, et al. Postoperative radiotherapyfor pancreatic cancer with microscopically-positive resectionmargin. Anticancer Res. 2017;37(2):755-764.
8. Tempero MA, Malafa MP, Chiorean EG, et al. PancreaticAdenocarcinoma, Version 1.2019. J Natl Compr Canc Netw.2019;17(3):202-210.
9. Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal andesophagogastric junction cancers, version 2.2019, NCCN ClinicalPractice Guidelines in Oncology. J Natl Compr Canc Netw.2019;17(7):855-883.
10. Ajani JA, Barthel JS, Bekaii-Saab T, et al. Gastric cancer. J NatlCompr Canc Netw. 2010;8(4):378-409.
11. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vsgemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreaticadenocarcinoma: a randomized controlled trial. JAMA.2008;299(9):1019-26.
12. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence ofresection margins on survival for patients with pancreatic cancertreated by adjuvant chemoradiation and/or chemotherapy in theESPAC-1 randomized controlled trial. Ann Surg. 2001;234(6):758-68.
13. Hsu CC, Herman JM, Corsini MM, et al. Adjuvantchemoradiation for pancreatic adenocarcinoma: the JohnsHopkins Hospital-Mayo Clinic collaborative study. Ann SurgOncol. 2010;17(4):981-90.
14. Herman JM, Swartz MJ, Hsu CC, et al. Analysis offluorouracil-based adjuvant chemotherapy and radiation afterpancreaticoduodenectomy for ductal adenocarcinoma of thepancreas: results of a large, prospectively collected database at theJohns Hopkins Hospital. J Clin Oncol. 2008;26(21):3503-10.
15. Corsini MM, Miller RC, Haddock MG, et al. Adjuvantradiotherapy and chemotherapy for pancreatic carcinoma:the Mayo Clinic experience (1975-2005). J Clin Oncol.2008;26(21):3511-6.
16. Butturini G, Stocken DD, Wente MN, et al. Influence of resectionmargins and treatment on survival in patients with pancreaticcancer: meta-analysis of randomized controlled trials. Arch Surg.2008;143(1):75-83.
17. Wo JY, Childs SK, Szymonifka J, et al. Delaying chemoradiationuntil after completion of adjuvant chemotherapy for pancreaticcancer may not impact local control. Pract Radiat Oncol.2014;4(2):e117-e123.
Article available in :
Volume 2, Issue 2, 2023
Page : 60-63
https://doi.org/10.51271/JTPM-0042
Article Information
Received : 01 Ağu 2023
Accepted : 28 Ağu 2023
Published : 31 Ağu 2023
Corresponding Author :

Hilal Alkış: Department of Radiation Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey

[email protected]
Citation : Alkış H, Arıkan R, Kornıenko A, Gündüz HK, Adlı M. Timing of adjuvant chemoradiation for pancreatic cancer with positive surgical margins. J Transl Pract Med. 2023;2(2):60-63.

Read: 273
Cited: 0
Download : 110
_Footer